Prognostic significance of NT-proBNP levels in patients treated with empagliflozin.

Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been added to the mainstay of treatment for chronic heart failure. Recent studies suggest that empagliflozin may also reverse cardiac remodeling in heart failure by reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. In our study, we wanted to show the decrease in NT-proBNP levels, which is an indicator of poor prognosis in heart failure, and to see if there was a decrease in the rate of renal progression in patients with HF after empagliflozin use.

The Comparison of QTc Dispersion Between Renal Transplant Recipients and Healthy Individuals.

Introduction Cardiovascular diseases are the most common cause of death in patients with end-stage renal failure. The increase in QTc interval time and QT dispersion increases the risk of cardiac arrhythmia and mortality. In our study, QT and QTc dispersions (QTcd) of patients who underwent renal transplantation were compared with normal healthy individuals.